15:22 , May 4, 2018 |  BC Week In Review  |  Company News

Accelerator launches Proniras to develop anticonvulsant

Accelerator Life Science Partners (Seattle, Wash.) launched newco Proniras Corp. (Seattle, Wash.) to develop tezampanel (LY293558) to treat nerve agent-induced seizures. Proniras has received an $89.5 million award from HHS’s Biomedical Advanced Research and Development...
19:57 , May 3, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

New Therapeutic Targets and Biomarkers: April 2018...
20:40 , Apr 27, 2018 |  BC Extra  |  Company News

Accelerator launches Proniras to develop anticonvulsant

Accelerator Life Science Partners (Seattle, Wash.) launched newco Proniras Corp. (Seattle, Wash.) to develop tezampanel (LY293558) to treat nerve agent-induced seizures. Proniras has received an $89.5 million award from HHS’s Biomedical Advanced Research and Development...